Zymeworks Inc. Common Shares (ZYME): Price and Financial Metrics

Zymeworks Inc. Common Shares (ZYME): $8.85

0.18 (+2.08%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ZYME to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#108 of 362

in industry

ZYME Price/Volume Stats

Current price $8.85 52-week high $13.14
Prev. close $8.67 52-week low $6.01
Day low $8.65 Volume 1,002,600
Day high $8.98 Avg. volume 575,562
50-day MA $10.76 Dividend yield N/A
200-day MA $8.83 Market Cap 624.53M

ZYME Stock Price Chart Interactive Chart >


Zymeworks Inc. Common Shares (ZYME) Company Bio


Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company was founded in 2003 and is based in Vancouver, BC.


ZYME Latest News Stream


Event/Time News Detail
Loading, please wait...

ZYME Latest Social Stream


Loading social stream, please wait...

View Full ZYME Social Stream

Latest ZYME News From Around the Web

Below are the latest news stories about ZYMEWORKS INC that investors may wish to consider to help them evaluate ZYME as an investment opportunity.

Small-Cap Sensations: 3 Stocks Predicted for Massive Growth in 2024

These three small-cap stocks have massive return potential in 2024 and beyond, according to analyst forecasts and broader industry trends.

Omor Ibne Ehsan on InvestorPlace | December 26, 2023

Zymeworks Announces $50 Million Private Placement to EcoR1 Capital

Proceeds expected to extend cash runway into H2 2027VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today announced that it had entered into a securities purchase agreement with funds affiliated with EcoR1 Capital, LLC (“EcoR1 Capital”), for the sale of an aggregate of 5,086,521 pre-funded warrants to purchase 5,086,521 shares of common stock, $0.00001 par v

Yahoo | December 26, 2023

From $10k to $100k in 5 years: 3 Small-Cap Stocks to Make a Fortune

Are you looking for small-cap stocks to get rich?

Yiannis Zourmpanos on InvestorPlace | December 25, 2023

Want to Turn Spare Change Into $1,000? Buy These 3 Stocks Now

Three high conviction stocks seem perfect for opportunistic investors and could quickly transform spare change into four-figure returns.

Omor Ibne Ehsan on InvestorPlace | December 18, 2023

Zymeworks Added to Nasdaq Biotechnology Index

VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, 2023. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market th

Yahoo | December 15, 2023

Read More 'ZYME' Stories Here

ZYME Price Returns

1-mo -15.87%
3-mo -13.91%
6-mo 26.97%
1-year -9.97%
3-year -68.78%
5-year -47.51%
YTD -14.82%
2023 32.19%
2022 -52.04%
2021 -65.32%
2020 3.96%
2019 209.67%

Continue Researching ZYME

Here are a few links from around the web to help you further your research on Zymeworks Inc's stock as an investment opportunity:

Zymeworks Inc (ZYME) Stock Price | Nasdaq
Zymeworks Inc (ZYME) Stock Quote, History and News - Yahoo Finance
Zymeworks Inc (ZYME) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!